Up next

Autoplay

Camrelizumab + Apatinib for Highrisk Chemorefractory or Relapsed Gestational Trophoblastic Neoplasia

1 Views • 06/30/23
Share
Embed
administrator
administrator
Subscribers
0

Warm Welcome to the latest OncoShorts podcast, brought to you by MedSynapse. OncoShorts covers a wide range of clinical and scientific medical content, that offers enriching insights into the World of Oncology.

In today’s podcast episode, we will discuss details of a randomized phase 2 trial, titled, Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia, featured in the November 2021 Issue of The Lancet Oncology.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay